id	sid	tid	token	lemma	pos
dpc-2446	1	1	dermatology	dermatology	NOUN
dpc-2446	1	2	:	:	PUNCT
dpc-2446	1	3	practical	practical	ADJ
dpc-2446	1	4	and	and	CCONJ
dpc-2446	1	5	conceptual	conceptual	ADJ
dpc-2446	1	6	research	research	NOUN
dpc-2446	1	7	letter	letter	NOUN
dpc-2446	2	1	|	|	ADV
dpc-2446	2	2	dermatol	dermatol	ADJ
dpc-2446	2	3	pract	pract	NOUN
dpc-2446	2	4	concept	concept	NOUN
dpc-2446	2	5	.	.	PUNCT
dpc-2446	3	1	2023;13(1):e2023022	2023;13(1):e2023022	NUM
dpc-2446	3	2	1	1	NUM
dpc-2446	3	3	regression	regression	NOUN
dpc-2446	3	4	of	of	ADP
dpc-2446	3	5	multiple	multiple	ADJ
dpc-2446	3	6	melanocytic	melanocytic	ADJ
dpc-2446	3	7	nevi	nevi	NOUN
dpc-2446	3	8	in	in	ADP
dpc-2446	3	9	two	two	NUM
dpc-2446	3	10	patients	patient	NOUN
dpc-2446	3	11	on	on	ADP
dpc-2446	3	12	nivolumab	nivolumab	NOUN
dpc-2446	3	13	for	for	ADP
dpc-2446	3	14	metastatic	metastatic	ADJ
dpc-2446	3	15	melanoma	melanoma	NOUN
dpc-2446	3	16	gloria	gloria	PROPN
dpc-2446	3	17	baeza	baeza	PROPN
dpc-2446	3	18	-	-	PUNCT
dpc-2446	3	19	hernández1	hernández1	PROPN
dpc-2446	3	20	,	,	PUNCT
dpc-2446	3	21	ricardo	ricardo	PROPN
dpc-2446	3	22	francisco	francisco	PROPN
dpc-2446	3	23	rubio	rubio	PROPN
dpc-2446	3	24	-	-	PUNCT
dpc-2446	3	25	aguilera1	aguilera1	PROPN
dpc-2446	3	26	,	,	PUNCT
dpc-2446	3	27	anastasia	anastasia	PROPN
dpc-2446	3	28	alejandra	alejandra	PROPN
dpc-2446	3	29	garrido	garrido	PROPN
dpc-2446	3	30	-	-	PUNCT
dpc-2446	3	31	ríos1	ríos1	PROPN
dpc-2446	3	32	,	,	PUNCT
dpc-2446	3	33	helena	helena	PROPN
dpc-2446	3	34	álvarez	álvarez	PROPN
dpc-2446	3	35	-	-	PUNCT
dpc-2446	3	36	garrido1	garrido1	PROPN
dpc-2446	3	37	,	,	PUNCT
dpc-2446	3	38	cristina	cristina	PROPN
dpc-2446	3	39	martínez	martínez	PROPN
dpc-2446	3	40	-	-	PUNCT
dpc-2446	3	41	morán1	morán1	PROPN
dpc-2446	3	42	,	,	PUNCT
dpc-2446	3	43	jesús	jesús	ADJ
dpc-2446	3	44	borbujo1	borbujo1	NOUN
dpc-2446	3	45	1	1	NUM
dpc-2446	3	46	department	department	NOUN
dpc-2446	3	47	of	of	ADP
dpc-2446	3	48	dermatology	dermatology	NOUN
dpc-2446	3	49	.	.	PUNCT
dpc-2446	4	1	hospital	hospital	NOUN
dpc-2446	4	2	universitario	universitario	PROPN
dpc-2446	4	3	de	de	PROPN
dpc-2446	4	4	fuenlabrada	fuenlabrada	PROPN
dpc-2446	4	5	,	,	PUNCT
dpc-2446	4	6	madrid	madrid	PROPN
dpc-2446	4	7	,	,	PUNCT
dpc-2446	4	8	spain	spain	PROPN
dpc-2446	4	9	key	key	ADJ
dpc-2446	4	10	words	word	NOUN
dpc-2446	4	11	:	:	PUNCT
dpc-2446	4	12	nivolumab	nivolumab	NOUN
dpc-2446	4	13	,	,	PUNCT
dpc-2446	4	14	regression	regression	NOUN
dpc-2446	4	15	,	,	PUNCT
dpc-2446	4	16	melanocytic	melanocytic	ADJ
dpc-2446	4	17	nevi	nevi	NOUN
dpc-2446	4	18	,	,	PUNCT
dpc-2446	4	19	melanoma	melanoma	NOUN
dpc-2446	4	20	,	,	PUNCT
dpc-2446	4	21	dermoscopy	dermoscopy	VERB
dpc-2446	4	22	citation	citation	NOUN
dpc-2446	4	23	:	:	PUNCT
dpc-2446	4	24	baezahernández	baezahernández	PROPN
dpc-2446	4	25	g	g	PROPN
dpc-2446	4	26	,	,	PUNCT
dpc-2446	4	27	rubio	rubio	NOUN
dpc-2446	4	28	-	-	PUNCT
dpc-2446	4	29	aguilera	aguilera	PROPN
dpc-2446	4	30	rf	rf	NOUN
dpc-2446	4	31	,	,	PUNCT
dpc-2446	4	32	garrido	garrido	X
dpc-2446	4	33	-	-	PUNCT
dpc-2446	4	34	ríos	ríos	PROPN
dpc-2446	4	35	aa	aa	PROPN
dpc-2446	4	36	,	,	PUNCT
dpc-2446	4	37	álvarez	álvarez	PROPN
dpc-2446	4	38	-	-	PUNCT
dpc-2446	4	39	garrido	garrido	PROPN
dpc-2446	4	40	h	h	NOUN
dpc-2446	4	41	,	,	PUNCT
dpc-2446	4	42	martínez	martínez	NOUN
dpc-2446	4	43	-	-	PUNCT
dpc-2446	4	44	morán	morán	PROPN
dpc-2446	4	45	c	c	PROPN
dpc-2446	4	46	,	,	PUNCT
dpc-2446	4	47	borbujo	borbujo	ADP
dpc-2446	4	48	j.	j.	PROPN
dpc-2446	4	49	regression	regression	PROPN
dpc-2446	4	50	of	of	ADP
dpc-2446	4	51	multiple	multiple	ADJ
dpc-2446	4	52	melanocytic	melanocytic	ADJ
dpc-2446	4	53	nevi	nevi	NOUN
dpc-2446	4	54	in	in	ADP
dpc-2446	4	55	two	two	NUM
dpc-2446	4	56	patients	patient	NOUN
dpc-2446	4	57	on	on	ADP
dpc-2446	4	58	nivolumab	nivolumab	NOUN
dpc-2446	4	59	for	for	ADP
dpc-2446	4	60	metastatic	metastatic	ADJ
dpc-2446	4	61	melanoma	melanoma	NOUN
dpc-2446	4	62	.	.	PUNCT
dpc-2446	5	1	dermatol	dermatol	NOUN
dpc-2446	5	2	pract	pract	PROPN
dpc-2446	5	3	concept	concept	NOUN
dpc-2446	5	4	.	.	PUNCT
dpc-2446	6	1	2023;13(1):e2023022	2023;13(1):e2023022	X
dpc-2446	6	2	.	.	PUNCT
dpc-2446	6	3	doi	doi	PROPN
dpc-2446	6	4	:	:	PUNCT
dpc-2446	6	5	https://doi.org/10.5826/dpc.1301a22	https://doi.org/10.5826/dpc.1301a22	PROPN
dpc-2446	6	6	accepted	accept	VERB
dpc-2446	6	7	:	:	PUNCT
dpc-2446	6	8	may	may	AUX
dpc-2446	6	9	26	26	NUM
dpc-2446	6	10	,	,	PUNCT
dpc-2446	6	11	2022	2022	NUM
dpc-2446	6	12	;	;	PUNCT
dpc-2446	6	13	published	publish	VERB
dpc-2446	6	14	:	:	PUNCT
dpc-2446	6	15	january	january	NOUN
dpc-2446	6	16	2023	2023	NUM
dpc-2446	7	1	copyright	copyright	NOUN
dpc-2446	7	2	:	:	PUNCT
dpc-2446	7	3	©	©	PROPN
dpc-2446	7	4	2023	2023	NUM
dpc-2446	7	5	baezahernández	baezahernández	PROPN
dpc-2446	7	6	et	et	PROPN
dpc-2446	7	7	al	al	PROPN
dpc-2446	7	8	.	.	PUNCT
dpc-2446	8	1	this	this	PRON
dpc-2446	8	2	is	be	AUX
dpc-2446	8	3	an	an	DET
dpc-2446	8	4	open	open	ADJ
dpc-2446	8	5	-	-	PUNCT
dpc-2446	8	6	access	access	NOUN
dpc-2446	8	7	article	article	NOUN
dpc-2446	8	8	distributed	distribute	VERB
dpc-2446	8	9	under	under	ADP
dpc-2446	8	10	the	the	DET
dpc-2446	8	11	terms	term	NOUN
dpc-2446	8	12	of	of	ADP
dpc-2446	8	13	the	the	DET
dpc-2446	8	14	creative	creative	ADJ
dpc-2446	8	15	commons	common	NOUN
dpc-2446	8	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-2446	8	17	license	license	NOUN
dpc-2446	8	18	(	(	PUNCT
dpc-2446	8	19	by	by	ADP
dpc-2446	8	20	-	-	PUNCT
dpc-2446	8	21	nc-4.0	nc-4.0	NOUN
dpc-2446	8	22	)	)	PUNCT
dpc-2446	8	23	,	,	PUNCT
dpc-2446	8	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-2446	8	25	,	,	PUNCT
dpc-2446	8	26	which	which	PRON
dpc-2446	8	27	permits	permit	VERB
dpc-2446	8	28	unrestricted	unrestricted	ADJ
dpc-2446	8	29	noncommercial	noncommercial	ADJ
dpc-2446	8	30	use	use	NOUN
dpc-2446	8	31	,	,	PUNCT
dpc-2446	8	32	distribution	distribution	NOUN
dpc-2446	8	33	,	,	PUNCT
dpc-2446	8	34	and	and	CCONJ
dpc-2446	8	35	reproduction	reproduction	NOUN
dpc-2446	8	36	in	in	ADP
dpc-2446	8	37	any	any	DET
dpc-2446	8	38	medium	medium	NOUN
dpc-2446	8	39	,	,	PUNCT
dpc-2446	8	40	provided	provide	VERB
dpc-2446	8	41	the	the	DET
dpc-2446	8	42	original	original	ADJ
dpc-2446	8	43	authors	author	NOUN
dpc-2446	8	44	and	and	CCONJ
dpc-2446	8	45	source	source	NOUN
dpc-2446	8	46	are	be	AUX
dpc-2446	8	47	credited	credit	VERB
dpc-2446	8	48	.	.	PUNCT
dpc-2446	9	1	funding	funding	NOUN
dpc-2446	9	2	:	:	PUNCT
dpc-2446	9	3	none	none	NOUN
dpc-2446	9	4	.	.	PUNCT
dpc-2446	10	1	competing	compete	VERB
dpc-2446	10	2	interests	interest	NOUN
dpc-2446	10	3	:	:	PUNCT
dpc-2446	10	4	none	none	NOUN
dpc-2446	10	5	.	.	PUNCT
dpc-2446	11	1	authorship	authorship	NOUN
dpc-2446	11	2	:	:	PUNCT
dpc-2446	11	3	all	all	DET
dpc-2446	11	4	authors	author	NOUN
dpc-2446	11	5	have	have	AUX
dpc-2446	11	6	contributed	contribute	VERB
dpc-2446	11	7	significantly	significantly	ADV
dpc-2446	11	8	to	to	ADP
dpc-2446	11	9	this	this	DET
dpc-2446	11	10	publication	publication	NOUN
dpc-2446	11	11	.	.	PUNCT
dpc-2446	12	1	corresponding	correspond	VERB
dpc-2446	12	2	author	author	NOUN
dpc-2446	12	3	:	:	PUNCT
dpc-2446	12	4	gloria	gloria	PROPN
dpc-2446	12	5	baeza	baeza	PROPN
dpc-2446	12	6	-	-	PUNCT
dpc-2446	12	7	hernández	hernández	PROPN
dpc-2446	12	8	,	,	PUNCT
dpc-2446	12	9	servicio	servicio	PROPN
dpc-2446	12	10	de	de	X
dpc-2446	12	11	dermatología	dermatología	PROPN
dpc-2446	12	12	,	,	PUNCT
dpc-2446	12	13	hospital	hospital	NOUN
dpc-2446	12	14	de	de	X
dpc-2446	12	15	fuenlabrada	fuenlabrada	PROPN
dpc-2446	12	16	,	,	PUNCT
dpc-2446	12	17	camino	camino	PROPN
dpc-2446	12	18	del	del	PROPN
dpc-2446	12	19	molino	molino	PROPN
dpc-2446	12	20	2	2	NUM
dpc-2446	12	21	,	,	PUNCT
dpc-2446	12	22	28942	28942	NUM
dpc-2446	12	23	fuenlabrada	fuenlabrada	PROPN
dpc-2446	12	24	,	,	PUNCT
dpc-2446	12	25	madrid	madrid	PROPN
dpc-2446	12	26	.	.	PUNCT
dpc-2446	13	1	e	e	X
dpc-2446	13	2	-	-	NOUN
dpc-2446	13	3	mail	mail	NOUN
dpc-2446	13	4	:	:	PUNCT
dpc-2446	13	5	gloria.baeza@salud.madrid.org	gloria.baeza@salud.madrid.org	PROPN
dpc-2446	13	6	introduction	introduction	NOUN
dpc-2446	13	7	immunotherapy	immunotherapy	NOUN
dpc-2446	13	8	(	(	PUNCT
dpc-2446	13	9	anti	anti	ADJ
dpc-2446	13	10	-	-	ADJ
dpc-2446	13	11	pd1	pd1	NOUN
dpc-2446	13	12	and	and	CCONJ
dpc-2446	13	13	anti	anti	ADJ
dpc-2446	13	14	-	-	ADJ
dpc-2446	13	15	ctla4	ctla4	ADJ
dpc-2446	13	16	)	)	PUNCT
dpc-2446	13	17	has	have	AUX
dpc-2446	13	18	been	be	AUX
dpc-2446	13	19	described	describe	VERB
dpc-2446	13	20	to	to	PART
dpc-2446	13	21	achieve	achieve	VERB
dpc-2446	13	22	complete	complete	ADJ
dpc-2446	13	23	regression	regression	NOUN
dpc-2446	13	24	of	of	ADP
dpc-2446	13	25	non	non	ADJ
dpc-2446	13	26	-	-	ADJ
dpc-2446	13	27	metastatic	metastatic	ADJ
dpc-2446	13	28	melanoma	melanoma	NOUN
dpc-2446	13	29	,	,	PUNCT
dpc-2446	13	30	assessed	assess	VERB
dpc-2446	13	31	by	by	ADP
dpc-2446	13	32	reflectance	reflectance	NOUN
dpc-2446	13	33	confocal	confocal	ADJ
dpc-2446	13	34	microscopy	microscopy	NOUN
dpc-2446	13	35	;	;	PUNCT
dpc-2446	13	36	however	however	ADV
dpc-2446	13	37	,	,	PUNCT
dpc-2446	13	38	their	their	PRON
dpc-2446	13	39	effects	effect	NOUN
dpc-2446	13	40	on	on	ADP
dpc-2446	13	41	benign	benign	ADJ
dpc-2446	13	42	melanocytic	melanocytic	ADJ
dpc-2446	13	43	lesions	lesion	NOUN
dpc-2446	13	44	have	have	AUX
dpc-2446	13	45	not	not	PART
dpc-2446	13	46	been	be	AUX
dpc-2446	13	47	thoroughly	thoroughly	ADV
dpc-2446	13	48	studied	study	VERB
dpc-2446	13	49	and	and	CCONJ
dpc-2446	13	50	may	may	AUX
dpc-2446	13	51	be	be	AUX
dpc-2446	13	52	underreported	underreporte	VERB
dpc-2446	13	53	 	 	SPACE
dpc-2446	14	1	[	[	X
dpc-2446	14	2	1	1	NUM
dpc-2446	14	3	]	]	PUNCT
dpc-2446	14	4	.	.	PUNCT
dpc-2446	15	1	herein	herein	NOUN
dpc-2446	15	2	we	we	PRON
dpc-2446	15	3	report	report	VERB
dpc-2446	15	4	2	2	NUM
dpc-2446	15	5	patients	patient	NOUN
dpc-2446	15	6	with	with	ADP
dpc-2446	15	7	regression	regression	NOUN
dpc-2446	15	8	of	of	ADP
dpc-2446	15	9	multiple	multiple	ADJ
dpc-2446	15	10	nevi	nevi	NOUN
dpc-2446	15	11	while	while	SCONJ
dpc-2446	15	12	on	on	ADP
dpc-2446	15	13	treatment	treatment	NOUN
dpc-2446	15	14	with	with	ADP
dpc-2446	15	15	nivolumab	nivolumab	NOUN
dpc-2446	15	16	for	for	ADP
dpc-2446	15	17	metastatic	metastatic	ADJ
dpc-2446	15	18	melanoma	melanoma	NOUN
dpc-2446	15	19	.	.	PUNCT
dpc-2446	16	1	case	case	NOUN
dpc-2446	16	2	presentation	presentation	NOUN
dpc-2446	16	3	two	two	NUM
dpc-2446	16	4	patients	patient	NOUN
dpc-2446	16	5	,	,	PUNCT
dpc-2446	16	6	suffering	suffer	VERB
dpc-2446	16	7	from	from	ADP
dpc-2446	16	8	metastatic	metastatic	ADJ
dpc-2446	16	9	melanoma	melanoma	NOUN
dpc-2446	16	10	treated	treat	VERB
dpc-2446	16	11	with	with	ADP
dpc-2446	16	12	nivolumab	nivolumab	NOUN
dpc-2446	16	13	(	(	PUNCT
dpc-2446	16	14	table	table	NOUN
dpc-2446	16	15	1	1	NUM
dpc-2446	16	16	)	)	PUNCT
dpc-2446	16	17	,	,	PUNCT
dpc-2446	16	18	attended	attend	VERB
dpc-2446	16	19	our	our	PRON
dpc-2446	16	20	outpatient	outpatient	NOUN
dpc-2446	16	21	clinic	clinic	NOUN
dpc-2446	16	22	for	for	ADP
dpc-2446	16	23	their	their	PRON
dpc-2446	16	24	annual	annual	ADJ
dpc-2446	16	25	digital	digital	ADJ
dpc-2446	16	26	dermoscopic	dermoscopic	NOUN
dpc-2446	16	27	monitoring	monitoring	NOUN
dpc-2446	16	28	.	.	PUNCT
dpc-2446	17	1	they	they	PRON
dpc-2446	17	2	were	be	AUX
dpc-2446	17	3	not	not	PART
dpc-2446	17	4	aware	aware	ADJ
dpc-2446	17	5	of	of	ADP
dpc-2446	17	6	any	any	DET
dpc-2446	17	7	changes	change	NOUN
dpc-2446	17	8	or	or	CCONJ
dpc-2446	17	9	new	new	ADJ
dpc-2446	17	10	melanocytic	melanocytic	ADJ
dpc-2446	17	11	lesions	lesion	NOUN
dpc-2446	17	12	.	.	PUNCT
dpc-2446	18	1	on	on	ADP
dpc-2446	18	2	physical	physical	ADJ
dpc-2446	18	3	examination	examination	NOUN
dpc-2446	18	4	,	,	PUNCT
dpc-2446	18	5	no	no	DET
dpc-2446	18	6	new	new	ADJ
dpc-2446	18	7	lesions	lesion	NOUN
dpc-2446	18	8	were	be	AUX
dpc-2446	18	9	detected	detect	VERB
dpc-2446	18	10	since	since	SCONJ
dpc-2446	18	11	their	their	PRON
dpc-2446	18	12	last	last	ADJ
dpc-2446	18	13	visit	visit	NOUN
dpc-2446	18	14	one	one	NUM
dpc-2446	18	15	year	year	NOUN
dpc-2446	18	16	before	before	ADV
dpc-2446	18	17	;	;	PUNCT
dpc-2446	18	18	with	with	ADP
dpc-2446	18	19	dermoscopy	dermoscopy	NOUN
dpc-2446	18	20	several	several	ADJ
dpc-2446	18	21	of	of	ADP
dpc-2446	18	22	their	their	PRON
dpc-2446	18	23	benign	benign	ADJ
dpc-2446	18	24	melanocytic	melanocytic	ADJ
dpc-2446	18	25	nevi	nevi	NOUN
dpc-2446	18	26	had	have	AUX
dpc-2446	18	27	lightened	lighten	VERB
dpc-2446	18	28	and	and	CCONJ
dpc-2446	18	29	no	no	DET
dpc-2446	18	30	atypical	atypical	ADJ
dpc-2446	18	31	or	or	CCONJ
dpc-2446	18	32	malignant	malignant	ADJ
dpc-2446	18	33	lesions	lesion	NOUN
dpc-2446	18	34	were	be	AUX
dpc-2446	18	35	observed	observe	VERB
dpc-2446	18	36	(	(	PUNCT
dpc-2446	18	37	figures	figure	NOUN
dpc-2446	18	38	1	1	NUM
dpc-2446	18	39	and	and	CCONJ
dpc-2446	18	40	2	2	NUM
dpc-2446	18	41	)	)	PUNCT
dpc-2446	18	42	.	.	PUNCT
dpc-2446	19	1	both	both	DET
dpc-2446	19	2	patients	patient	NOUN
dpc-2446	19	3	had	have	AUX
dpc-2446	19	4	experienced	experience	VERB
dpc-2446	19	5	disease	disease	NOUN
dpc-2446	19	6	progression	progression	NOUN
dpc-2446	19	7	despite	despite	SCONJ
dpc-2446	19	8	anti	anti	ADJ
dpc-2446	19	9	-	-	ADJ
dpc-2446	19	10	pd1	pd1	ADJ
dpc-2446	19	11	treatment	treatment	NOUN
dpc-2446	19	12	.	.	PUNCT
dpc-2446	20	1	conclusions	conclusion	NOUN
dpc-2446	20	2	benign	benign	ADJ
dpc-2446	20	3	melanocytic	melanocytic	ADJ
dpc-2446	20	4	nevi	nevi	ADJ
dpc-2446	20	5	regression	regression	NOUN
dpc-2446	20	6	is	be	AUX
dpc-2446	20	7	an	an	DET
dpc-2446	20	8	emerging	emerge	VERB
dpc-2446	20	9	secondary	secondary	ADJ
dpc-2446	20	10	effect	effect	NOUN
dpc-2446	20	11	of	of	ADP
dpc-2446	20	12	anti	anti	ADJ
dpc-2446	20	13	-	-	ADJ
dpc-2446	20	14	pd1	pd1	VERB
dpc-2446	20	15	drugs	drug	NOUN
dpc-2446	20	16	nivolumab	nivolumab	ADV
dpc-2446	20	17	and	and	CCONJ
dpc-2446	20	18	pembrolizumab	pembrolizumab	NOUN
dpc-2446	20	19	.	.	PUNCT
dpc-2446	21	1	although	although	SCONJ
dpc-2446	21	2	these	these	DET
dpc-2446	21	3	drugs	drug	NOUN
dpc-2446	21	4	are	be	AUX
dpc-2446	21	5	used	use	VERB
dpc-2446	21	6	on	on	ADP
dpc-2446	21	7	other	other	ADJ
dpc-2446	21	8	cancer	cancer	NOUN
dpc-2446	21	9	treatments	treatment	NOUN
dpc-2446	21	10	,	,	PUNCT
dpc-2446	21	11	this	this	DET
dpc-2446	21	12	secondary	secondary	ADJ
dpc-2446	21	13	effect	effect	NOUN
dpc-2446	21	14	seems	seem	VERB
dpc-2446	21	15	to	to	PART
dpc-2446	21	16	be	be	AUX
dpc-2446	21	17	more	more	ADV
dpc-2446	21	18	frequent	frequent	ADJ
dpc-2446	21	19	in	in	ADP
dpc-2446	21	20	patients	patient	NOUN
dpc-2446	21	21	undergoing	undergo	VERB
dpc-2446	21	22	treatment	treatment	NOUN
dpc-2446	21	23	for	for	ADP
dpc-2446	21	24	melanoma	melanoma	NOUN
dpc-2446	21	25	[	[	X
dpc-2446	21	26	2	2	NUM
dpc-2446	21	27	]	]	PUNCT
dpc-2446	21	28	.	.	PUNCT
dpc-2446	22	1	in	in	ADP
dpc-2446	22	2	an	an	DET
dpc-2446	22	3	observational	observational	ADJ
dpc-2446	22	4	study	study	NOUN
dpc-2446	22	5	published	publish	VERB
dpc-2446	22	6	in	in	ADP
dpc-2446	22	7	2017	2017	NUM
dpc-2446	22	8	,	,	PUNCT
dpc-2446	22	9	11	11	NUM
dpc-2446	22	10	patients	patient	NOUN
dpc-2446	22	11	treated	treat	VERB
dpc-2446	22	12	2	2	NUM
dpc-2446	22	13	research	research	NOUN
dpc-2446	22	14	letter	letter	NOUN
dpc-2446	23	1	|	|	ADV
dpc-2446	23	2	dermatol	dermatol	ADJ
dpc-2446	23	3	pract	pract	NOUN
dpc-2446	23	4	concept	concept	NOUN
dpc-2446	23	5	.	.	PUNCT
dpc-2446	24	1	2023;13(1):e2023022	2023;13(1):e2023022	NUM
dpc-2446	24	2	with	with	ADP
dpc-2446	24	3	anti	anti	NOUN
dpc-2446	24	4	-	-	ADJ
dpc-2446	24	5	pd1	pd1	VERB
dpc-2446	24	6	for	for	ADP
dpc-2446	24	7	metastatic	metastatic	ADJ
dpc-2446	24	8	melanoma	melanoma	NOUN
dpc-2446	24	9	(	(	PUNCT
dpc-2446	24	10	10	10	NUM
dpc-2446	24	11	with	with	ADP
dpc-2446	24	12	pembrolizumab	pembrolizumab	NOUN
dpc-2446	24	13	and	and	CCONJ
dpc-2446	24	14	1	1	NUM
dpc-2446	24	15	with	with	ADP
dpc-2446	24	16	nivolumab	nivolumab	NOUN
dpc-2446	24	17	)	)	PUNCT
dpc-2446	24	18	had	have	VERB
dpc-2446	24	19	more	more	ADV
dpc-2446	24	20	lightened	lightened	ADJ
dpc-2446	24	21	nevi	nevi	NOUN
dpc-2446	24	22	than	than	ADP
dpc-2446	24	23	controls	control	NOUN
dpc-2446	24	24	during	during	ADP
dpc-2446	24	25	follow	follow	NOUN
dpc-2446	24	26	-	-	PUNCT
dpc-2446	24	27	up	up	NOUN
dpc-2446	24	28	(	(	PUNCT
dpc-2446	24	29	49	49	NUM
dpc-2446	24	30	%	%	NOUN
dpc-2446	24	31	versus	versus	ADP
dpc-2446	24	32	19	19	NUM
dpc-2446	24	33	%	%	NOUN
dpc-2446	24	34	)	)	PUNCT
dpc-2446	24	35	;	;	PUNCT
dpc-2446	24	36	nevertheless	nevertheless	ADV
dpc-2446	24	37	,	,	PUNCT
dpc-2446	24	38	differences	difference	NOUN
dpc-2446	24	39	were	be	AUX
dpc-2446	24	40	not	not	PART
dpc-2446	24	41	statistically	statistically	ADV
dpc-2446	24	42	significant	significant	ADJ
dpc-2446	24	43	[	[	X
dpc-2446	24	44	3	3	NUM
dpc-2446	24	45	]	]	PUNCT
dpc-2446	24	46	.	.	PUNCT
dpc-2446	25	1	lightening	lighten	VERB
dpc-2446	25	2	without	without	ADP
dpc-2446	25	3	halo	halo	NOUN
dpc-2446	25	4	is	be	AUX
dpc-2446	25	5	a	a	DET
dpc-2446	25	6	known	known	ADJ
dpc-2446	25	7	phenomenon	phenomenon	NOUN
dpc-2446	25	8	,	,	PUNCT
dpc-2446	25	9	especially	especially	ADV
dpc-2446	25	10	in	in	ADP
dpc-2446	25	11	patients	patient	NOUN
dpc-2446	25	12	treated	treat	VERB
dpc-2446	25	13	with	with	ADP
dpc-2446	25	14	pembrolizumab	pembrolizumab	NOUN
dpc-2446	25	15	[	[	X
dpc-2446	25	16	4,5	4,5	NUM
dpc-2446	25	17	]	]	PUNCT
dpc-2446	25	18	.	.	PUNCT
dpc-2446	26	1	there	there	PRON
dpc-2446	26	2	are	be	VERB
dpc-2446	26	3	few	few	ADJ
dpc-2446	26	4	reports	report	NOUN
dpc-2446	26	5	regarding	regard	VERB
dpc-2446	26	6	regression	regression	NOUN
dpc-2446	26	7	of	of	ADP
dpc-2446	26	8	melanocytic	melanocytic	ADJ
dpc-2446	26	9	nevi	nevi	NOUN
dpc-2446	26	10	in	in	ADP
dpc-2446	26	11	patients	patient	NOUN
dpc-2446	26	12	treated	treat	VERB
dpc-2446	26	13	with	with	ADP
dpc-2446	26	14	nivolumab	nivolumab	NOUN
dpc-2446	26	15	:	:	PUNCT
dpc-2446	26	16	one	one	NUM
dpc-2446	26	17	similar	similar	ADJ
dpc-2446	26	18	to	to	ADP
dpc-2446	26	19	our	our	PRON
dpc-2446	26	20	patient	patient	NOUN
dpc-2446	26	21	,	,	PUNCT
dpc-2446	26	22	with	with	ADP
dpc-2446	26	23	no	no	DET
dpc-2446	26	24	inflammation	inflammation	NOUN
dpc-2446	26	25	or	or	CCONJ
dpc-2446	26	26	halo	halo	NOUN
dpc-2446	26	27	,	,	PUNCT
dpc-2446	26	28	and	and	CCONJ
dpc-2446	26	29	another	another	DET
dpc-2446	26	30	patient	patient	NOUN
dpc-2446	26	31	who	who	PRON
dpc-2446	26	32	experimented	experiment	VERB
dpc-2446	26	33	inflammation	inflammation	NOUN
dpc-2446	26	34	before	before	ADP
dpc-2446	26	35	regression	regression	NOUN
dpc-2446	26	36	,	,	PUNCT
dpc-2446	26	37	with	with	ADP
dpc-2446	26	38	no	no	DET
dpc-2446	26	39	halo	halo	NOUN
dpc-2446	26	40	[	[	X
dpc-2446	26	41	6,7	6,7	NUM
dpc-2446	26	42	]	]	PUNCT
dpc-2446	26	43	.	.	PUNCT
dpc-2446	27	1	though	though	SCONJ
dpc-2446	27	2	some	some	DET
dpc-2446	27	3	articles	article	NOUN
dpc-2446	27	4	suggest	suggest	VERB
dpc-2446	27	5	that	that	SCONJ
dpc-2446	27	6	regression	regression	NOUN
dpc-2446	27	7	of	of	ADP
dpc-2446	27	8	melanocytic	melanocytic	ADJ
dpc-2446	27	9	nevi	nevi	NOUN
dpc-2446	27	10	may	may	AUX
dpc-2446	27	11	be	be	AUX
dpc-2446	27	12	related	relate	VERB
dpc-2446	27	13	to	to	ADP
dpc-2446	27	14	the	the	DET
dpc-2446	27	15	therapeutic	therapeutic	ADJ
dpc-2446	27	16	effect	effect	NOUN
dpc-2446	27	17	of	of	ADP
dpc-2446	27	18	the	the	DET
dpc-2446	27	19	anti	anti	ADJ
dpc-2446	27	20	-	-	ADJ
dpc-2446	27	21	pd1	pd1	ADJ
dpc-2446	27	22	drug	drug	NOUN
dpc-2446	27	23	and	and	CCONJ
dpc-2446	27	24	could	could	AUX
dpc-2446	27	25	be	be	AUX
dpc-2446	27	26	interpreted	interpret	VERB
dpc-2446	27	27	as	as	ADP
dpc-2446	27	28	a	a	DET
dpc-2446	27	29	sign	sign	NOUN
dpc-2446	27	30	of	of	ADP
dpc-2446	27	31	good	good	ADJ
dpc-2446	27	32	therapeutical	therapeutical	ADJ
dpc-2446	27	33	response	response	NOUN
dpc-2446	27	34	,	,	PUNCT
dpc-2446	27	35	our	our	PRON
dpc-2446	27	36	patients	patient	NOUN
dpc-2446	27	37	both	both	CCONJ
dpc-2446	27	38	experimented	experiment	VERB
dpc-2446	27	39	progression	progression	NOUN
dpc-2446	27	40	despite	despite	SCONJ
dpc-2446	27	41	nivolumab	nivolumab	NOUN
dpc-2446	27	42	treatment	treatment	NOUN
dpc-2446	27	43	;	;	PUNCT
dpc-2446	27	44	therefore	therefore	ADV
dpc-2446	27	45	,	,	PUNCT
dpc-2446	27	46	more	more	ADJ
dpc-2446	27	47	studies	study	NOUN
dpc-2446	27	48	are	be	AUX
dpc-2446	27	49	required	require	VERB
dpc-2446	27	50	to	to	PART
dpc-2446	27	51	shed	shed	VERB
dpc-2446	27	52	light	light	NOUN
dpc-2446	27	53	on	on	ADP
dpc-2446	27	54	this	this	DET
dpc-2446	27	55	matter	matter	NOUN
dpc-2446	27	56	[	[	X
dpc-2446	27	57	2,5,7	2,5,7	NUM
dpc-2446	27	58	]	]	PUNCT
dpc-2446	27	59	.	.	PUNCT
dpc-2446	28	1	one	one	NUM
dpc-2446	28	2	of	of	ADP
dpc-2446	28	3	our	our	PRON
dpc-2446	28	4	patients	patient	NOUN
dpc-2446	28	5	also	also	ADV
dpc-2446	28	6	had	have	VERB
dpc-2446	28	7	vitiligo	vitiligo	NOUN
dpc-2446	28	8	-	-	PUNCT
dpc-2446	28	9	like	like	ADJ
dpc-2446	28	10	phenomenon	phenomenon	NOUN
dpc-2446	28	11	,	,	PUNCT
dpc-2446	28	12	which	which	PRON
dpc-2446	28	13	has	have	AUX
dpc-2446	28	14	been	be	AUX
dpc-2446	28	15	suggested	suggest	VERB
dpc-2446	28	16	to	to	PART
dpc-2446	28	17	be	be	AUX
dpc-2446	28	18	associated	associate	VERB
dpc-2446	28	19	with	with	ADP
dpc-2446	28	20	a	a	DET
dpc-2446	28	21	better	well	ADJ
dpc-2446	28	22	prognosis	prognosis	NOUN
dpc-2446	28	23	[	[	X
dpc-2446	28	24	2	2	NUM
dpc-2446	28	25	]	]	PUNCT
dpc-2446	28	26	.	.	PUNCT
dpc-2446	29	1	furthermore	furthermore	ADV
dpc-2446	29	2	,	,	PUNCT
dpc-2446	29	3	some	some	DET
dpc-2446	29	4	other	other	ADJ
dpc-2446	29	5	questions	question	NOUN
dpc-2446	29	6	remain	remain	VERB
dpc-2446	29	7	still	still	ADV
dpc-2446	29	8	unanswered	unanswered	ADJ
dpc-2446	29	9	:	:	PUNCT
dpc-2446	29	10	it	it	PRON
dpc-2446	29	11	could	could	AUX
dpc-2446	29	12	be	be	AUX
dpc-2446	29	13	asked	ask	VERB
dpc-2446	29	14	why	why	SCONJ
dpc-2446	29	15	some	some	DET
dpc-2446	29	16	patients	patient	NOUN
dpc-2446	29	17	experience	experience	VERB
dpc-2446	29	18	only	only	ADV
dpc-2446	29	19	lightening	lighten	VERB
dpc-2446	29	20	without	without	ADP
dpc-2446	29	21	halo	halo	NOUN
dpc-2446	29	22	,	,	PUNCT
dpc-2446	29	23	while	while	SCONJ
dpc-2446	29	24	others	other	NOUN
dpc-2446	29	25	have	have	VERB
dpc-2446	29	26	vitiligo	vitiligo	NOUN
dpc-2446	29	27	-	-	PUNCT
dpc-2446	29	28	like	like	ADJ
dpc-2446	29	29	reactions	reaction	NOUN
dpc-2446	29	30	and	and	CCONJ
dpc-2446	29	31	halo	halo	NOUN
dpc-2446	29	32	nevi	nevi	PROPN
dpc-2446	29	33	,	,	PUNCT
dpc-2446	29	34	and	and	CCONJ
dpc-2446	29	35	whether	whether	SCONJ
dpc-2446	29	36	the	the	DET
dpc-2446	29	37	underlying	underlying	ADJ
dpc-2446	29	38	mechanism	mechanism	NOUN
dpc-2446	29	39	is	be	AUX
dpc-2446	29	40	the	the	DET
dpc-2446	29	41	same	same	ADJ
dpc-2446	29	42	[	[	X
dpc-2446	29	43	3	3	NUM
dpc-2446	29	44	]	]	PUNCT
dpc-2446	29	45	;	;	PUNCT
dpc-2446	29	46	why	why	SCONJ
dpc-2446	29	47	some	some	DET
dpc-2446	29	48	patients	patient	NOUN
dpc-2446	29	49	have	have	VERB
dpc-2446	29	50	clinical	clinical	ADJ
dpc-2446	29	51	inflammation	inflammation	NOUN
dpc-2446	29	52	but	but	CCONJ
dpc-2446	29	53	most	most	ADJ
dpc-2446	29	54	of	of	ADP
dpc-2446	29	55	them	they	PRON
dpc-2446	29	56	do	do	AUX
dpc-2446	29	57	not	not	PART
dpc-2446	29	58	according	accord	VERB
dpc-2446	29	59	to	to	ADP
dpc-2446	29	60	the	the	DET
dpc-2446	29	61	literature	literature	NOUN
dpc-2446	29	62	.	.	PUNCT
dpc-2446	30	1	lastly	lastly	ADV
dpc-2446	30	2	,	,	PUNCT
dpc-2446	30	3	it	it	PRON
dpc-2446	30	4	is	be	AUX
dpc-2446	30	5	debatable	debatable	ADJ
dpc-2446	30	6	whether	whether	SCONJ
dpc-2446	30	7	regression	regression	NOUN
dpc-2446	30	8	of	of	ADP
dpc-2446	30	9	nevi	nevi	NOUN
dpc-2446	30	10	with	with	ADP
dpc-2446	30	11	anti	anti	ADJ
dpc-2446	30	12	-	-	ADJ
dpc-2446	30	13	pd1	pd1	NOUN
dpc-2446	30	14	is	be	AUX
dpc-2446	30	15	as	as	ADV
dpc-2446	30	16	rare	rare	ADJ
dpc-2446	30	17	as	as	SCONJ
dpc-2446	30	18	it	it	PRON
dpc-2446	30	19	seems	seem	VERB
dpc-2446	30	20	today	today	NOUN
dpc-2446	30	21	,	,	PUNCT
dpc-2446	30	22	for	for	SCONJ
dpc-2446	30	23	it	it	PRON
dpc-2446	30	24	may	may	AUX
dpc-2446	30	25	be	be	AUX
dpc-2446	30	26	an	an	DET
dpc-2446	30	27	unnoticed	unnoticed	ADJ
dpc-2446	30	28	secondary	secondary	ADJ
dpc-2446	30	29	effect	effect	NOUN
dpc-2446	30	30	in	in	ADP
dpc-2446	30	31	other	other	ADJ
dpc-2446	30	32	cancer	cancer	NOUN
dpc-2446	30	33	patients	patient	NOUN
dpc-2446	30	34	(	(	PUNCT
dpc-2446	30	35	lung	lung	NOUN
dpc-2446	30	36	,	,	PUNCT
dpc-2446	30	37	table	table	NOUN
dpc-2446	30	38	1	1	NUM
dpc-2446	30	39	.	.	PUNCT
dpc-2446	30	40	patient	patient	ADJ
dpc-2446	30	41	characteristics	characteristic	NOUN
dpc-2446	30	42	.	.	PUNCT
dpc-2446	31	1	metastatic	metastatic	ADJ
dpc-2446	31	2	melanoma	melanoma	NOUN
dpc-2446	31	3	patient	patient	ADJ
dpc-2446	31	4	1	1	NUM
dpc-2446	31	5	patient	patient	NOUN
dpc-2446	31	6	2	2	NUM
dpc-2446	31	7	sex	sex	NOUN
dpc-2446	31	8	male	male	ADJ
dpc-2446	31	9	male	male	ADJ
dpc-2446	31	10	age	age	NOUN
dpc-2446	31	11	,	,	PUNCT
dpc-2446	31	12	years	year	NOUN
dpc-2446	31	13	50	50	NUM
dpc-2446	31	14	60	60	NUM
dpc-2446	31	15	location	location	NOUN
dpc-2446	31	16	abdomen	abdomen	VERB
dpc-2446	31	17	back	back	ADP
dpc-2446	31	18	mutation	mutation	NOUN
dpc-2446	31	19	braf	braf	NOUN
dpc-2446	31	20	v600e	v600e	PROPN
dpc-2446	31	21	/	/	SYM
dpc-2446	31	22	e2	e2	PROPN
dpc-2446	31	23	/	/	SYM
dpc-2446	31	24	d	d	NOUN
dpc-2446	31	25	treatment	treatment	NOUN
dpc-2446	31	26	before	before	ADV
dpc-2446	31	27	/	/	SYM
dpc-2446	31	28	after	after	ADP
dpc-2446	31	29	nivolumab	nivolumab	NOUN
dpc-2446	31	30	before	before	ADV
dpc-2446	31	31	:	:	PUNCT
dpc-2446	31	32	dabrafenib	dabrafenib	NOUN
dpc-2446	31	33	-	-	PUNCT
dpc-2446	31	34	trametinib	trametinib	NOUN
dpc-2446	31	35	,	,	PUNCT
dpc-2446	31	36	which	which	PRON
dpc-2446	31	37	was	be	AUX
dpc-2446	31	38	stopped	stop	VERB
dpc-2446	31	39	because	because	SCONJ
dpc-2446	31	40	metastases	metastasis	NOUN
dpc-2446	31	41	spread	spread	VERB
dpc-2446	31	42	to	to	ADP
dpc-2446	31	43	his	his	PRON
dpc-2446	31	44	lungs	lung	NOUN
dpc-2446	31	45	and	and	CCONJ
dpc-2446	31	46	inguinal	inguinal	ADJ
dpc-2446	31	47	and	and	CCONJ
dpc-2446	31	48	retroperitoneal	retroperitoneal	ADJ
dpc-2446	31	49	lymph	lymph	NOUN
dpc-2446	31	50	nodes	node	NOUN
dpc-2446	31	51	(	(	PUNCT
dpc-2446	31	52	lymphadenectomy	lymphadenectomy	NOUN
dpc-2446	31	53	was	be	AUX
dpc-2446	31	54	performed	perform	VERB
dpc-2446	31	55	)	)	PUNCT
dpc-2446	32	1	no	no	DET
dpc-2446	32	2	nivolumab	nivolumab	NOUN
dpc-2446	32	3	start	start	VERB
dpc-2446	32	4	and	and	CCONJ
dpc-2446	32	5	end	end	VERB
dpc-2446	32	6	dates	date	NOUN
dpc-2446	32	7	/	/	SYM
dpc-2446	32	8	doses	dose	NOUN
dpc-2446	32	9	mg	mg	NOUN
dpc-2446	32	10	/	/	SYM
dpc-2446	32	11	weeks	week	NOUN
dpc-2446	32	12	2021	2021	NUM
dpc-2446	32	13	–	–	PUNCT
dpc-2446	32	14	ongoing/	ongoing/	NUM
dpc-2446	32	15	240	240	NUM
dpc-2446	32	16	mg	mg	NOUN
dpc-2446	32	17	every	every	DET
dpc-2446	32	18	2	2	NUM
dpc-2446	32	19	weeks	week	NOUN
dpc-2446	32	20	2020	2020	NUM
dpc-2446	32	21	-	-	SYM
dpc-2446	32	22	2021/	2021/	NUM
dpc-2446	32	23	480	480	NUM
dpc-2446	32	24	mg	mg	NOUN
dpc-2446	32	25	every	every	DET
dpc-2446	32	26	4	4	NUM
dpc-2446	32	27	weeks	week	NOUN
dpc-2446	32	28	lightening	lighten	VERB
dpc-2446	32	29	of	of	ADP
dpc-2446	32	30	nevi	nevi	NOUN
dpc-2446	32	31	observed	observe	VERB
dpc-2446	32	32	with	with	ADP
dpc-2446	32	33	digital	digital	ADJ
dpc-2446	32	34	dermoscopy	dermoscopy	NOUN
dpc-2446	32	35	2021	2021	NUM
dpc-2446	32	36	:	:	PUNCT
dpc-2446	32	37	>	>	X
dpc-2446	32	38	80	80	NUM
dpc-2446	32	39	%	%	NOUN
dpc-2446	32	40	of	of	ADP
dpc-2446	32	41	his	his	PRON
dpc-2446	32	42	nevi	nevi	NOUN
dpc-2446	32	43	.	.	PUNCT
dpc-2446	33	1	(	(	PUNCT
dpc-2446	33	2	previous	previous	ADJ
dpc-2446	33	3	digital	digital	ADJ
dpc-2446	33	4	monitoring	monitoring	NOUN
dpc-2446	33	5	:	:	PUNCT
dpc-2446	33	6	2020	2020	NUM
dpc-2446	33	7	)	)	PUNCT
dpc-2446	33	8	2022	2022	NUM
dpc-2446	33	9	:	:	PUNCT
dpc-2446	33	10	>	>	X
dpc-2446	33	11	60	60	NUM
dpc-2446	33	12	%	%	NOUN
dpc-2446	33	13	of	of	ADP
dpc-2446	33	14	his	his	PRON
dpc-2446	33	15	nevi	nevi	NOUN
dpc-2446	33	16	.	.	PUNCT
dpc-2446	34	1	(	(	PUNCT
dpc-2446	34	2	previous	previous	ADJ
dpc-2446	34	3	digital	digital	ADJ
dpc-2446	34	4	monitoring	monitoring	NOUN
dpc-2446	34	5	:	:	PUNCT
dpc-2446	34	6	2021	2021	NUM
dpc-2446	34	7	)	)	PUNCT
dpc-2446	34	8	nivolumab	nivolumab	ADP
dpc-2446	34	9	secondary	secondary	ADJ
dpc-2446	34	10	effects	effect	NOUN
dpc-2446	34	11	yes	yes	ADV
dpc-2446	34	12	,	,	PUNCT
dpc-2446	34	13	vitiligo	vitiligo	NOUN
dpc-2446	34	14	-	-	PUNCT
dpc-2446	34	15	like	like	ADJ
dpc-2446	34	16	lesions	lesion	NOUN
dpc-2446	34	17	yes	yes	INTJ
dpc-2446	34	18	,	,	PUNCT
dpc-2446	34	19	nivolumab	nivolumab	ADV
dpc-2446	34	20	-	-	PUNCT
dpc-2446	34	21	induced	induce	VERB
dpc-2446	34	22	thyrotoxicosis	thyrotoxicosis	NOUN
dpc-2446	34	23	and	and	CCONJ
dpc-2446	34	24	subsequent	subsequent	ADJ
dpc-2446	34	25	hypothyroidism	hypothyroidism	NOUN
dpc-2446	34	26	disease	disease	NOUN
dpc-2446	34	27	progression	progression	NOUN
dpc-2446	34	28	while	while	SCONJ
dpc-2446	34	29	on	on	ADP
dpc-2446	34	30	nivolumab	nivolumab	NOUN
dpc-2446	34	31	yes	yes	INTJ
dpc-2446	34	32	,	,	PUNCT
dpc-2446	34	33	new	new	ADJ
dpc-2446	34	34	lymph	lymph	NOUN
dpc-2446	34	35	node	node	NOUN
dpc-2446	34	36	metastases	metastasis	NOUN
dpc-2446	34	37	near	near	ADP
dpc-2446	34	38	his	his	PRON
dpc-2446	34	39	melanoma	melanoma	NOUN
dpc-2446	34	40	scar	scar	NOUN
dpc-2446	34	41	on	on	ADP
dpc-2446	34	42	the	the	DET
dpc-2446	34	43	abdomen	abdoman	NOUN
dpc-2446	34	44	and	and	CCONJ
dpc-2446	34	45	small	small	ADJ
dpc-2446	34	46	bowel	bowel	NOUN
dpc-2446	34	47	metastases	metastasis	NOUN
dpc-2446	34	48	(	(	PUNCT
dpc-2446	34	49	2022	2022	NUM
dpc-2446	34	50	)	)	PUNCT
dpc-2446	35	1	yes	yes	INTJ
dpc-2446	35	2	,	,	PUNCT
dpc-2446	35	3	dermal	dermal	VERB
dpc-2446	35	4	melanoma	melanoma	NOUN
dpc-2446	35	5	metastases	metastasis	NOUN
dpc-2446	35	6	on	on	ADP
dpc-2446	35	7	the	the	DET
dpc-2446	35	8	back	back	NOUN
dpc-2446	35	9	(	(	PUNCT
dpc-2446	35	10	2021	2021	NUM
dpc-2446	35	11	)	)	PUNCT
dpc-2446	35	12	second	second	ADJ
dpc-2446	35	13	melanoma	melanoma	NOUN
dpc-2446	35	14	while	while	SCONJ
dpc-2446	35	15	on	on	ADP
dpc-2446	35	16	treatment	treatment	NOUN
dpc-2446	35	17	yes	yes	INTJ
dpc-2446	35	18	,	,	PUNCT
dpc-2446	35	19	melanoma	melanoma	NOUN
dpc-2446	35	20	in	in	ADP
dpc-2446	35	21	situ	situ	NOUN
dpc-2446	35	22	on	on	ADP
dpc-2446	35	23	his	his	PRON
dpc-2446	35	24	back	back	NOUN
dpc-2446	35	25	while	while	SCONJ
dpc-2446	35	26	on	on	ADP
dpc-2446	35	27	dabrafenibtrametinib	dabrafenibtrametinib	NOUN
dpc-2446	35	28	(	(	PUNCT
dpc-2446	35	29	2020	2020	NUM
dpc-2446	35	30	)	)	PUNCT
dpc-2446	35	31	.	.	PUNCT
dpc-2446	36	1	yes	yes	INTJ
dpc-2446	36	2	,	,	PUNCT
dpc-2446	36	3	melanoma	melanoma	NOUN
dpc-2446	36	4	on	on	ADP
dpc-2446	36	5	his	his	PRON
dpc-2446	36	6	right	right	ADJ
dpc-2446	36	7	leg	leg	NOUN
dpc-2446	36	8	(	(	PUNCT
dpc-2446	36	9	breslow	breslow	ADJ
dpc-2446	36	10	thickness	thickness	NOUN
dpc-2446	36	11	3.4	3.4	NUM
dpc-2446	36	12	mm	mm	NOUN
dpc-2446	36	13	)	)	PUNCT
dpc-2446	36	14	while	while	SCONJ
dpc-2446	36	15	on	on	ADP
dpc-2446	36	16	nivolumab	nivolumab	NOUN
dpc-2446	36	17	(	(	PUNCT
dpc-2446	36	18	2021	2021	NUM
dpc-2446	36	19	)	)	PUNCT
dpc-2446	36	20	.	.	PUNCT
dpc-2446	37	1	both	both	PRON
dpc-2446	37	2	were	be	AUX
dpc-2446	37	3	detected	detect	VERB
dpc-2446	37	4	in	in	ADP
dpc-2446	37	5	the	the	DET
dpc-2446	37	6	annual	annual	ADJ
dpc-2446	37	7	digital	digital	ADJ
dpc-2446	37	8	dermoscopy	dermoscopy	NOUN
dpc-2446	37	9	monitoring	monitoring	NOUN
dpc-2446	37	10	visit	visit	NOUN
dpc-2446	37	11	.	.	PUNCT
dpc-2446	38	1	other	other	ADJ
dpc-2446	38	2	a	a	DET
dpc-2446	38	3	lung	lung	NOUN
dpc-2446	38	4	adenocarcinoma	adenocarcinoma	NOUN
dpc-2446	38	5	was	be	AUX
dpc-2446	38	6	diagnosed	diagnose	VERB
dpc-2446	38	7	while	while	SCONJ
dpc-2446	38	8	on	on	ADP
dpc-2446	38	9	nivolumab	nivolumab	NOUN
dpc-2446	38	10	(	(	PUNCT
dpc-2446	38	11	2021	2021	NUM
dpc-2446	38	12	)	)	PUNCT
dpc-2446	38	13	and	and	CCONJ
dpc-2446	38	14	later	later	ADV
dpc-2446	38	15	excised	excise	VERB
dpc-2446	38	16	.	.	PUNCT
dpc-2446	39	1	he	he	PRON
dpc-2446	39	2	has	have	AUX
dpc-2446	39	3	developed	develop	VERB
dpc-2446	39	4	mediastinal	mediastinal	ADJ
dpc-2446	39	5	lymph	lymph	NOUN
dpc-2446	39	6	node	node	NOUN
dpc-2446	39	7	metastases	metastasis	NOUN
dpc-2446	39	8	,	,	PUNCT
dpc-2446	39	9	awaiting	await	VERB
dpc-2446	39	10	treatment	treatment	NOUN
dpc-2446	39	11	.	.	PUNCT
dpc-2446	40	1	research	research	NOUN
dpc-2446	40	2	letter	letter	NOUN
dpc-2446	40	3	|	|	ADV
dpc-2446	40	4	dermatol	dermatol	ADJ
dpc-2446	40	5	pract	pract	NOUN
dpc-2446	40	6	concept	concept	NOUN
dpc-2446	40	7	.	.	PUNCT
dpc-2446	41	1	2023;13(1):e2023022	2023;13(1):e2023022	NUM
dpc-2446	41	2	3	3	NUM
dpc-2446	41	3	figure	figure	NOUN
dpc-2446	41	4	1	1	NUM
dpc-2446	41	5	.	.	PUNCT
dpc-2446	41	6	clinical	clinical	ADJ
dpc-2446	41	7	images	image	NOUN
dpc-2446	41	8	of	of	ADP
dpc-2446	41	9	patient	patient	NOUN
dpc-2446	41	10	1	1	NUM
dpc-2446	41	11	:	:	SYM
dpc-2446	41	12	2020	2020	NUM
dpc-2446	41	13	(	(	PUNCT
dpc-2446	41	14	left	leave	VERB
dpc-2446	41	15	)	)	PUNCT
dpc-2446	41	16	and	and	CCONJ
dpc-2446	41	17	2021	2021	NUM
dpc-2446	41	18	(	(	PUNCT
dpc-2446	41	19	right	right	NOUN
dpc-2446	41	20	)	)	PUNCT
dpc-2446	41	21	.	.	PUNCT
dpc-2446	42	1	three	three	NUM
dpc-2446	42	2	examples	example	NOUN
dpc-2446	42	3	of	of	ADP
dpc-2446	42	4	lesions	lesion	NOUN
dpc-2446	42	5	registered	register	VERB
dpc-2446	42	6	in	in	ADP
dpc-2446	42	7	digital	digital	ADJ
dpc-2446	42	8	monitoring	monitoring	NOUN
dpc-2446	42	9	of	of	ADP
dpc-2446	42	10	patient	patient	NOUN
dpc-2446	42	11	1	1	NUM
dpc-2446	42	12	.	.	PUNCT
dpc-2446	42	13	(	(	PUNCT
dpc-2446	42	14	a1	a1	NOUN
dpc-2446	42	15	-	-	PUNCT
dpc-2446	42	16	c1	c1	NOUN
dpc-2446	42	17	)	)	PUNCT
dpc-2446	42	18	first	first	ADJ
dpc-2446	42	19	row	row	NOUN
dpc-2446	42	20	shows	show	VERB
dpc-2446	42	21	these	these	DET
dpc-2446	42	22	benign	benign	ADJ
dpc-2446	42	23	melanocytic	melanocytic	NOUN
dpc-2446	42	24	in	in	ADP
dpc-2446	42	25	2020	2020	NUM
dpc-2446	42	26	.	.	PUNCT
dpc-2446	43	1	(	(	PUNCT
dpc-2446	43	2	a2	a2	NOUN
dpc-2446	43	3	-	-	PUNCT
dpc-2446	43	4	c2	c2	PROPN
dpc-2446	43	5	)	)	PUNCT
dpc-2446	43	6	second	second	ADJ
dpc-2446	43	7	row	row	NOUN
dpc-2446	43	8	shows	show	VERB
dpc-2446	43	9	the	the	DET
dpc-2446	43	10	same	same	ADJ
dpc-2446	43	11	lesions	lesion	NOUN
dpc-2446	43	12	one	one	NUM
dpc-2446	43	13	year	year	NOUN
dpc-2446	43	14	later	later	ADV
dpc-2446	43	15	in	in	ADP
dpc-2446	43	16	2021	2021	NUM
dpc-2446	43	17	,	,	PUNCT
dpc-2446	43	18	6	6	NUM
dpc-2446	43	19	months	month	NOUN
dpc-2446	43	20	after	after	ADP
dpc-2446	43	21	starting	start	VERB
dpc-2446	43	22	treatment	treatment	NOUN
dpc-2446	43	23	with	with	ADP
dpc-2446	43	24	nivolumab	nivolumab	NOUN
dpc-2446	43	25	.	.	PUNCT
dpc-2446	44	1	kidney	kidney	NOUN
dpc-2446	44	2	,	,	PUNCT
dpc-2446	44	3	head	head	NOUN
dpc-2446	44	4	,	,	PUNCT
dpc-2446	44	5	and	and	CCONJ
dpc-2446	44	6	neck	neck	NOUN
dpc-2446	44	7	,	,	PUNCT
dpc-2446	44	8	etc	etc	X
dpc-2446	44	9	.	.	X
dpc-2446	44	10	)	)	PUNCT
dpc-2446	44	11	who	who	PRON
dpc-2446	44	12	are	be	AUX
dpc-2446	44	13	not	not	PART
dpc-2446	44	14	followed	follow	VERB
dpc-2446	44	15	up	up	ADP
dpc-2446	44	16	in	in	ADP
dpc-2446	44	17	a	a	DET
dpc-2446	44	18	dermatology	dermatology	NOUN
dpc-2446	44	19	clinic	clinic	NOUN
dpc-2446	44	20	.	.	PUNCT
dpc-2446	45	1	one	one	PRON
dpc-2446	45	2	may	may	AUX
dpc-2446	45	3	well	well	ADV
dpc-2446	45	4	wonder	wonder	VERB
dpc-2446	45	5	about	about	ADP
dpc-2446	45	6	the	the	DET
dpc-2446	45	7	utility	utility	NOUN
dpc-2446	45	8	of	of	ADP
dpc-2446	45	9	digital	digital	ADJ
dpc-2446	45	10	monitoring	monitoring	NOUN
dpc-2446	45	11	of	of	ADP
dpc-2446	45	12	patients	patient	NOUN
dpc-2446	45	13	with	with	ADP
dpc-2446	45	14	metastatic	metastatic	ADJ
dpc-2446	45	15	melanoma	melanoma	NOUN
dpc-2446	45	16	undergoing	undergo	VERB
dpc-2446	45	17	treatment	treatment	NOUN
dpc-2446	45	18	with	with	ADP
dpc-2446	45	19	immune	immune	ADJ
dpc-2446	45	20	checkpoint	checkpoint	NOUN
dpc-2446	45	21	inhibitors	inhibitor	NOUN
dpc-2446	45	22	(	(	PUNCT
dpc-2446	45	23	ici	ici	PROPN
dpc-2446	45	24	)	)	PUNCT
dpc-2446	45	25	.	.	PUNCT
dpc-2446	46	1	in	in	ADP
dpc-2446	46	2	a	a	DET
dpc-2446	46	3	recent	recent	ADJ
dpc-2446	46	4	single	single	ADJ
dpc-2446	46	5	-	-	PUNCT
dpc-2446	46	6	center	center	NOUN
dpc-2446	46	7	retrospective	retrospective	ADJ
dpc-2446	46	8	cohort	cohort	NOUN
dpc-2446	46	9	study	study	NOUN
dpc-2446	46	10	42	42	NUM
dpc-2446	46	11	patients	patient	NOUN
dpc-2446	46	12	(	(	PUNCT
dpc-2446	46	13	1.9	1.9	NUM
dpc-2446	46	14	%	%	NOUN
dpc-2446	46	15	)	)	PUNCT
dpc-2446	46	16	with	with	ADP
dpc-2446	46	17	metastatic	metastatic	ADJ
dpc-2446	46	18	melanoma	melanoma	NOUN
dpc-2446	46	19	who	who	PRON
dpc-2446	46	20	received	receive	VERB
dpc-2446	46	21	treatment	treatment	NOUN
dpc-2446	46	22	with	with	ADP
dpc-2446	46	23	ici	ici	NOUN
dpc-2446	46	24	developed	develop	VERB
dpc-2446	46	25	new	new	ADJ
dpc-2446	46	26	melanomas	melanoma	NOUN
dpc-2446	46	27	;	;	PUNCT
dpc-2446	46	28	thus	thus	ADV
dpc-2446	46	29	,	,	PUNCT
dpc-2446	46	30	prospective	prospective	ADJ
dpc-2446	46	31	studies	study	NOUN
dpc-2446	46	32	with	with	ADP
dpc-2446	46	33	longer	long	ADJ
dpc-2446	46	34	follow	follow	VERB
dpc-2446	46	35	-	-	PUNCT
dpc-2446	46	36	up	up	NOUN
dpc-2446	46	37	are	be	AUX
dpc-2446	46	38	needed	need	VERB
dpc-2446	46	39	to	to	PART
dpc-2446	46	40	draw	draw	VERB
dpc-2446	46	41	a	a	DET
dpc-2446	46	42	solid	solid	ADJ
dpc-2446	46	43	conclusion	conclusion	NOUN
dpc-2446	46	44	[	[	X
dpc-2446	46	45	8	8	NUM
dpc-2446	46	46	]	]	PUNCT
dpc-2446	46	47	.	.	PUNCT
dpc-2446	47	1	while	while	SCONJ
dpc-2446	47	2	on	on	ADP
dpc-2446	47	3	ici	ici	PROPN
dpc-2446	47	4	,	,	PUNCT
dpc-2446	47	5	both	both	PRON
dpc-2446	47	6	of	of	ADP
dpc-2446	47	7	our	our	PRON
dpc-2446	47	8	patients	patient	NOUN
dpc-2446	47	9	had	have	VERB
dpc-2446	47	10	a	a	DET
dpc-2446	47	11	second	second	ADJ
dpc-2446	47	12	melanoma	melanoma	NOUN
dpc-2446	47	13	that	that	PRON
dpc-2446	47	14	was	be	AUX
dpc-2446	47	15	detected	detect	VERB
dpc-2446	47	16	in	in	ADP
dpc-2446	47	17	the	the	DET
dpc-2446	47	18	digital	digital	ADJ
dpc-2446	47	19	follow	follow	NOUN
dpc-2446	47	20	-	-	PUNCT
dpc-2446	47	21	up	up	NOUN
dpc-2446	47	22	;	;	PUNCT
dpc-2446	47	23	we	we	PRON
dpc-2446	47	24	want	want	VERB
dpc-2446	47	25	to	to	PART
dpc-2446	47	26	highlight	highlight	VERB
dpc-2446	47	27	that	that	SCONJ
dpc-2446	47	28	in	in	ADP
dpc-2446	47	29	case	case	NOUN
dpc-2446	47	30	1	1	NUM
dpc-2446	47	31	,	,	PUNCT
dpc-2446	47	32	with	with	ADP
dpc-2446	47	33	longer	long	ADJ
dpc-2446	47	34	digital	digital	ADJ
dpc-2446	47	35	monitoring	monitoring	NOUN
dpc-2446	47	36	,	,	PUNCT
dpc-2446	47	37	melanoma	melanoma	PROPN
dpc-2446	47	38	was	be	AUX
dpc-2446	47	39	detected	detect	VERB
dpc-2446	47	40	in	in	ADP
dpc-2446	47	41	situ	situ	NOUN
dpc-2446	47	42	,	,	PUNCT
dpc-2446	47	43	in	in	ADP
dpc-2446	47	44	line	line	NOUN
dpc-2446	47	45	with	with	ADP
dpc-2446	47	46	the	the	DET
dpc-2446	47	47	findings	finding	NOUN
dpc-2446	47	48	of	of	ADP
dpc-2446	47	49	lallas	lallas	PROPN
dpc-2446	47	50	et	et	PROPN
dpc-2446	47	51	al	al	PROPN
dpc-2446	47	52	where	where	SCONJ
dpc-2446	47	53	almost	almost	ADV
dpc-2446	47	54	70	70	NUM
dpc-2446	47	55	%	%	NOUN
dpc-2446	47	56	of	of	ADP
dpc-2446	47	57	second	second	ADJ
dpc-2446	47	58	primary	primary	ADJ
dpc-2446	47	59	melanomas	melanomas	NOUN
dpc-2446	47	60	detected	detect	VERB
dpc-2446	47	61	during	during	ADP
dpc-2446	47	62	surveillance	surveillance	NOUN
dpc-2446	47	63	were	be	AUX
dpc-2446	47	64	in	in	ADP
dpc-2446	47	65	situ	situ	NOUN
dpc-2446	47	66	[	[	X
dpc-2446	47	67	9	9	NUM
dpc-2446	47	68	]	]	PUNCT
dpc-2446	47	69	.	.	PUNCT
dpc-2446	48	1	we	we	PRON
dpc-2446	48	2	think	think	VERB
dpc-2446	48	3	that	that	SCONJ
dpc-2446	48	4	,	,	PUNCT
dpc-2446	48	5	when	when	SCONJ
dpc-2446	48	6	available	available	ADJ
dpc-2446	48	7	and	and	CCONJ
dpc-2446	48	8	feasible	feasible	ADJ
dpc-2446	48	9	,	,	PUNCT
dpc-2446	48	10	monitoring	monitor	VERB
dpc-2446	48	11	with	with	ADP
dpc-2446	48	12	digital	digital	ADJ
dpc-2446	48	13	dermoscopy	dermoscopy	NOUN
dpc-2446	48	14	and	and	CCONJ
dpc-2446	48	15	total	total	ADJ
dpc-2446	48	16	body	body	NOUN
dpc-2446	48	17	photography	photography	NOUN
dpc-2446	48	18	should	should	AUX
dpc-2446	48	19	be	be	AUX
dpc-2446	48	20	offered	offer	VERB
dpc-2446	48	21	to	to	ADP
dpc-2446	48	22	all	all	DET
dpc-2446	48	23	melanoma	melanoma	NOUN
dpc-2446	48	24	patients	patient	NOUN
dpc-2446	48	25	,	,	PUNCT
dpc-2446	48	26	as	as	SCONJ
dpc-2446	48	27	it	it	PRON
dpc-2446	48	28	helps	help	VERB
dpc-2446	48	29	in	in	ADP
dpc-2446	48	30	the	the	DET
dpc-2446	48	31	early	early	ADJ
dpc-2446	48	32	diagnosis	diagnosis	NOUN
dpc-2446	48	33	of	of	ADP
dpc-2446	48	34	melanoma	melanoma	NOUN
dpc-2446	48	35	,	,	PUNCT
dpc-2446	48	36	with	with	SCONJ
dpc-2446	48	37	some	some	DET
dpc-2446	48	38	lesions	lesion	NOUN
dpc-2446	48	39	being	be	AUX
dpc-2446	48	40	only	only	ADV
dpc-2446	48	41	diagnosed	diagnose	VERB
dpc-2446	48	42	by	by	ADP
dpc-2446	48	43	dermoscopic	dermoscopic	ADJ
dpc-2446	48	44	changes	change	NOUN
dpc-2446	48	45	in	in	ADP
dpc-2446	48	46	the	the	DET
dpc-2446	48	47	absence	absence	NOUN
dpc-2446	48	48	of	of	ADP
dpc-2446	48	49	melanoma	melanoma	NOUN
dpc-2446	48	50	-	-	PUNCT
dpc-2446	48	51	specific	specific	ADJ
dpc-2446	48	52	criteria	criterion	NOUN
dpc-2446	49	1	[	[	X
dpc-2446	49	2	9	9	NUM
dpc-2446	49	3	]	]	PUNCT
dpc-2446	49	4	.	.	PUNCT
dpc-2446	50	1	regression	regression	NOUN
dpc-2446	50	2	of	of	ADP
dpc-2446	50	3	multiple	multiple	ADJ
dpc-2446	50	4	nevi	nevi	NOUN
dpc-2446	50	5	is	be	AUX
dpc-2446	50	6	a	a	DET
dpc-2446	50	7	scarcely	scarcely	ADV
dpc-2446	50	8	reported	report	VERB
dpc-2446	50	9	secondary	secondary	ADJ
dpc-2446	50	10	effect	effect	NOUN
dpc-2446	50	11	of	of	ADP
dpc-2446	50	12	nivolumab	nivolumab	NOUN
dpc-2446	50	13	we	we	PRON
dpc-2446	50	14	should	should	AUX
dpc-2446	50	15	be	be	AUX
dpc-2446	50	16	aware	aware	ADJ
dpc-2446	50	17	of	of	ADP
dpc-2446	50	18	,	,	PUNCT
dpc-2446	50	19	especially	especially	ADV
dpc-2446	50	20	in	in	ADP
dpc-2446	50	21	dermoscopic	dermoscopic	ADJ
dpc-2446	50	22	monitoring	monitoring	NOUN
dpc-2446	50	23	.	.	PUNCT
dpc-2446	51	1	it	it	PRON
dpc-2446	51	2	may	may	AUX
dpc-2446	51	3	be	be	AUX
dpc-2446	51	4	an	an	DET
dpc-2446	51	5	overlooked	overlook	VERB
dpc-2446	51	6	effect	effect	NOUN
dpc-2446	51	7	because	because	SCONJ
dpc-2446	51	8	patients	patient	NOUN
dpc-2446	51	9	treated	treat	VERB
dpc-2446	51	10	with	with	ADP
dpc-2446	51	11	anti	anti	ADJ
dpc-2446	51	12	-	-	ADJ
dpc-2446	51	13	pd1	pd1	VERB
dpc-2446	51	14	for	for	ADP
dpc-2446	51	15	cancers	cancer	NOUN
dpc-2446	51	16	other	other	ADJ
dpc-2446	51	17	than	than	ADP
dpc-2446	51	18	melanoma	melanoma	NOUN
dpc-2446	51	19	are	be	AUX
dpc-2446	51	20	not	not	PART
dpc-2446	51	21	usually	usually	ADV
dpc-2446	51	22	examined	examine	VERB
dpc-2446	51	23	by	by	ADP
dpc-2446	51	24	a	a	DET
dpc-2446	51	25	dermatologist	dermatologist	NOUN
dpc-2446	51	26	.	.	PUNCT
dpc-2446	52	1	its	its	PRON
dpc-2446	52	2	prognostic	prognostic	ADJ
dpc-2446	52	3	meaning	meaning	NOUN
dpc-2446	52	4	is	be	AUX
dpc-2446	52	5	still	still	ADV
dpc-2446	52	6	unclear	unclear	ADJ
dpc-2446	52	7	.	.	PUNCT
dpc-2446	53	1	4	4	NUM
dpc-2446	53	2	research	research	NOUN
dpc-2446	53	3	letter	letter	NOUN
dpc-2446	53	4	|	|	ADV
dpc-2446	53	5	dermatol	dermatol	ADJ
dpc-2446	53	6	pract	pract	NOUN
dpc-2446	53	7	concept	concept	NOUN
dpc-2446	53	8	.	.	PUNCT
dpc-2446	54	1	2023;13(1):e2023022	2023;13(1):e2023022	NUM
dpc-2446	54	2	4	4	NUM
dpc-2446	54	3	.	.	PUNCT
dpc-2446	54	4	wolner	wolner	PROPN
dpc-2446	54	5	zj	zj	PROPN
dpc-2446	54	6	,	,	PUNCT
dpc-2446	54	7	marghoob	marghoob	VERB
dpc-2446	54	8	aa	aa	PROPN
dpc-2446	54	9	,	,	PUNCT
dpc-2446	54	10	pulitzer	pulitzer	PROPN
dpc-2446	54	11	mp	mp	PROPN
dpc-2446	54	12	,	,	PUNCT
dpc-2446	54	13	postow	postow	PROPN
dpc-2446	54	14	ma	ma	PROPN
dpc-2446	54	15	,	,	PUNCT
dpc-2446	54	16	marchetti	marchetti	PROPN
dpc-2446	54	17	ma	ma	PROPN
dpc-2446	54	18	.	.	PROPN
dpc-2446	55	1	a	a	DET
dpc-2446	55	2	case	case	NOUN
dpc-2446	55	3	report	report	NOUN
dpc-2446	55	4	of	of	ADP
dpc-2446	55	5	disappearing	disappear	VERB
dpc-2446	55	6	pigmented	pigmented	ADJ
dpc-2446	55	7	skin	skin	NOUN
dpc-2446	55	8	lesions	lesion	NOUN
dpc-2446	55	9	associated	associate	VERB
dpc-2446	55	10	with	with	ADP
dpc-2446	55	11	pembrolizumab	pembrolizumab	NOUN
dpc-2446	55	12	treatment	treatment	NOUN
dpc-2446	55	13	for	for	ADP
dpc-2446	55	14	metastatic	metastatic	ADJ
dpc-2446	55	15	melanoma	melanoma	NOUN
dpc-2446	55	16	.	.	PUNCT
dpc-2446	56	1	br	br	PROPN
dpc-2446	56	2	j	j	PROPN
dpc-2446	56	3	dermatol	dermatol	NOUN
dpc-2446	56	4	.	.	PUNCT
dpc-2446	57	1	2018;178(1):265	2018;178(1):265	NUM
dpc-2446	57	2	-	-	SYM
dpc-2446	57	3	269	269	NUM
dpc-2446	57	4	.	.	PUNCT
dpc-2446	57	5	doi:10.1111	doi:10.1111	ADJ
dpc-2446	57	6	/	/	SYM
dpc-2446	57	7	bjd.15354	bjd.15354	PROPN
dpc-2446	57	8	.	.	PUNCT
dpc-2446	58	1	pmid	pmid	NOUN
dpc-2446	58	2	:	:	PUNCT
dpc-2446	58	3	28132411	28132411	NUM
dpc-2446	58	4	.	.	PUNCT
dpc-2446	59	1	pmcid	pmcid	ADJ
dpc-2446	59	2	:	:	PUNCT
dpc-2446	59	3	pmc5533648	pmc5533648	NOUN
dpc-2446	59	4	.	.	PUNCT
dpc-2446	60	1	5	5	X
dpc-2446	60	2	.	.	X
dpc-2446	60	3	mauzo	mauzo	PROPN
dpc-2446	60	4	sh	sh	PROPN
dpc-2446	60	5	,	,	PUNCT
dpc-2446	60	6	tetzlaff	tetzlaff	PROPN
dpc-2446	60	7	mt	mt	PROPN
dpc-2446	60	8	,	,	PUNCT
dpc-2446	60	9	nelson	nelson	PROPN
dpc-2446	60	10	k	k	PROPN
dpc-2446	60	11	,	,	PUNCT
dpc-2446	60	12	et	et	PROPN
dpc-2446	60	13	al	al	PROPN
dpc-2446	60	14	.	.	PROPN
dpc-2446	60	15	regressed	regress	VERB
dpc-2446	60	16	melanocytic	melanocytic	ADJ
dpc-2446	60	17	nevi	nevi	ADJ
dpc-2446	60	18	secondary	secondary	ADJ
dpc-2446	60	19	to	to	ADP
dpc-2446	60	20	pembrolizumab	pembrolizumab	NOUN
dpc-2446	60	21	therapy	therapy	NOUN
dpc-2446	60	22	:	:	PUNCT
dpc-2446	60	23	an	an	DET
dpc-2446	60	24	emerging	emerge	VERB
dpc-2446	60	25	melanocytic	melanocytic	ADJ
dpc-2446	60	26	dermatologic	dermatologic	ADJ
dpc-2446	60	27	effect	effect	NOUN
dpc-2446	60	28	from	from	ADP
dpc-2446	60	29	immune	immune	ADJ
dpc-2446	60	30	checkpoint	checkpoint	NOUN
dpc-2446	60	31	antibody	antibody	NOUN
dpc-2446	60	32	blockade	blockade	NOUN
dpc-2446	60	33	.	.	PUNCT
dpc-2446	61	1	int	int	NOUN
dpc-2446	61	2	j	j	PROPN
dpc-2446	61	3	dermatol	dermatol	NOUN
dpc-2446	61	4	.	.	PUNCT
dpc-2446	62	1	2019;58(9):1045	2019;58(9):1045	NUM
dpc-2446	62	2	-	-	SYM
dpc-2446	62	3	1052	1052	NUM
dpc-2446	62	4	.	.	PUNCT
dpc-2446	63	1	doi:10.1111	doi:10.1111	PROPN
dpc-2446	63	2	/ijd.13833	/ijd.13833	PROPN
dpc-2446	63	3	.	.	PUNCT
dpc-2446	64	1	pmid	pmid	NOUN
dpc-2446	64	2	:	:	PUNCT
dpc-2446	64	3	29152725	29152725	NUM
dpc-2446	64	4	.	.	PUNCT
dpc-2446	65	1	6	6	NUM
dpc-2446	65	2	.	.	X
dpc-2446	65	3	vazquez	vazquez	PROPN
dpc-2446	65	4	b	b	PROPN
dpc-2446	65	5	,	,	PUNCT
dpc-2446	65	6	velasco	velasco	PROPN
dpc-2446	65	7	r	r	PROPN
dpc-2446	65	8	,	,	PUNCT
dpc-2446	65	9	martin	martin	PROPN
dpc-2446	65	10	jm	jm	PROPN
dpc-2446	65	11	,	,	PUNCT
dpc-2446	65	12	gonzalez	gonzalez	PROPN
dpc-2446	65	13	i	i	PROPN
dpc-2446	65	14	,	,	PUNCT
dpc-2446	65	15	ramon	ramon	PROPN
dpc-2446	65	16	md	md	PROPN
dpc-2446	65	17	.	.	PROPN
dpc-2446	65	18	regression	regression	PROPN
dpc-2446	65	19	  	  	SPACE
dpc-2446	65	20	of	of	ADP
dpc-2446	65	21	multiple	multiple	ADJ
dpc-2446	65	22	melanocytic	melanocytic	ADJ
dpc-2446	65	23	nevi	nevi	NOUN
dpc-2446	65	24	associated	associate	VERB
dpc-2446	65	25	with	with	ADP
dpc-2446	65	26	nivolumab	nivolumab	NOUN
dpc-2446	65	27	treatment	treatment	NOUN
dpc-2446	65	28	  	  	SPACE
dpc-2446	65	29	for	for	ADP
dpc-2446	65	30	metastatic	metastatic	ADJ
dpc-2446	65	31	melanoma	melanoma	NOUN
dpc-2446	65	32	.	.	PUNCT
dpc-2446	66	1	int	int	NOUN
dpc-2446	66	2	j	j	PROPN
dpc-2446	66	3	dermatol	dermatol	NOUN
dpc-2446	66	4	.	.	PUNCT
dpc-2446	67	1	2019;58(11):1331	2019;58(11):1331	NUM
dpc-2446	67	2	-	-	SYM
dpc-2446	67	3	1333	1333	NUM
dpc-2446	67	4	.	.	PUNCT
dpc-2446	68	1	doi:10.1111	doi:10.1111	NOUN
dpc-2446	68	2	/	/	SYM
dpc-2446	68	3	ijd.14340	ijd.14340	PROPN
dpc-2446	68	4	.	.	PUNCT
dpc-2446	69	1	pmid	pmid	NOUN
dpc-2446	69	2	:	:	PUNCT
dpc-2446	69	3	30536371	30536371	NUM
dpc-2446	69	4	.	.	PUNCT
dpc-2446	70	1	7	7	X
dpc-2446	70	2	.	.	X
dpc-2446	70	3	nakamura	nakamura	PROPN
dpc-2446	70	4	y	y	PROPN
dpc-2446	70	5	,	,	PUNCT
dpc-2446	70	6	fujino	fujino	PROPN
dpc-2446	70	7	t	t	PROPN
dpc-2446	70	8	,	,	PUNCT
dpc-2446	70	9	kagamu	kagamu	PROPN
dpc-2446	70	10	h	h	PROPN
dpc-2446	70	11	,	,	PUNCT
dpc-2446	70	12	et	et	PROPN
dpc-2446	70	13	al	al	PROPN
dpc-2446	70	14	.	.	PROPN
dpc-2446	70	15	induction	induction	NOUN
dpc-2446	70	16	of	of	ADP
dpc-2446	70	17	immune	immune	ADJ
dpc-2446	70	18	reaction	reaction	NOUN
dpc-2446	70	19	in	in	ADP
dpc-2446	70	20	benign	benign	ADJ
dpc-2446	70	21	melanocytic	melanocytic	ADJ
dpc-2446	70	22	nevi	nevi	NOUN
dpc-2446	70	23	without	without	ADP
dpc-2446	70	24	halo	halo	NOUN
dpc-2446	70	25	during	during	ADP
dpc-2446	70	26	nivolumab	nivolumab	NOUN
dpc-2446	70	27	therapy	therapy	NOUN
dpc-2446	70	28	in	in	ADP
dpc-2446	70	29	a	a	DET
dpc-2446	70	30	patient	patient	NOUN
dpc-2446	70	31	with	with	ADP
dpc-2446	70	32	melanoma	melanoma	NOUN
dpc-2446	70	33	.	.	PUNCT
dpc-2446	71	1	jama	jama	PROPN
dpc-2446	71	2	dermatology	dermatology	PROPN
dpc-2446	71	3	.	.	PUNCT
dpc-2446	72	1	2017;153(8):832	2017;153(8):832	X
dpc-2446	72	2	-	-	PUNCT
dpc-2446	72	3	834	834	NUM
dpc-2446	72	4	.	.	PUNCT
dpc-2446	73	1	doi:10.1001	doi:10.1001	PROPN
dpc-2446	73	2	/	/	SYM
dpc-2446	73	3	jamadermatol.2017.0615	jamadermatol.2017.0615	PROPN
dpc-2446	73	4	.	.	PUNCT
dpc-2446	74	1	pmid	pmid	NOUN
dpc-2446	74	2	:	:	PUNCT
dpc-2446	74	3	28492864	28492864	NUM
dpc-2446	74	4	.	.	PUNCT
dpc-2446	75	1	references	reference	NOUN
dpc-2446	75	2	1	1	NUM
dpc-2446	75	3	.	.	PUNCT
dpc-2446	76	1	navarrete	navarrete	ADJ
dpc-2446	76	2	-	-	PUNCT
dpc-2446	76	3	dechent	dechent	NOUN
dpc-2446	76	4	c	c	NOUN
dpc-2446	76	5	,	,	PUNCT
dpc-2446	76	6	cordova	cordova	PROPN
dpc-2446	76	7	m	m	PROPN
dpc-2446	76	8	,	,	PUNCT
dpc-2446	76	9	postow	postow	PROPN
dpc-2446	76	10	ma	ma	PROPN
dpc-2446	76	11	,	,	PUNCT
dpc-2446	76	12	et	et	PROPN
dpc-2446	76	13	al	al	PROPN
dpc-2446	76	14	.	.	PUNCT
dpc-2446	76	15	evaluation	evaluation	NOUN
dpc-2446	76	16	of	of	ADP
dpc-2446	76	17	the	the	DET
dpc-2446	76	18	response	response	NOUN
dpc-2446	76	19	of	of	ADP
dpc-2446	76	20	unresectable	unresectable	ADJ
dpc-2446	76	21	primary	primary	ADJ
dpc-2446	76	22	cutaneous	cutaneous	ADJ
dpc-2446	76	23	melanoma	melanoma	NOUN
dpc-2446	76	24	to	to	ADP
dpc-2446	76	25	immunotherapy	immunotherapy	NOUN
dpc-2446	76	26	visualized	visualize	VERB
dpc-2446	76	27	with	with	ADP
dpc-2446	76	28	reflectance	reflectance	NOUN
dpc-2446	76	29	confocal	confocal	ADJ
dpc-2446	76	30	microscopy	microscopy	NOUN
dpc-2446	76	31	.	.	PUNCT
dpc-2446	77	1	jama	jama	PROPN
dpc-2446	77	2	dermatology	dermatology	PROPN
dpc-2446	77	3	.	.	PUNCT
dpc-2446	78	1	2019;155(3):347	2019;155(3):347	NUM
dpc-2446	78	2	.	.	PUNCT
dpc-2446	79	1	doi:10.1001	doi:10.1001	PROPN
dpc-2446	79	2	/	/	SYM
dpc-2446	79	3	jamadermatol.2018.3688	jamadermatol.2018.3688	PROPN
dpc-2446	79	4	.	.	PUNCT
dpc-2446	80	1	pmid	pmid	NOUN
dpc-2446	80	2	:	:	PUNCT
dpc-2446	80	3	30624578	30624578	NUM
dpc-2446	80	4	.	.	PUNCT
dpc-2446	81	1	pmcid	pmcid	ADJ
dpc-2446	81	2	:	:	PUNCT
dpc-2446	81	3	pmc6440283	pmc6440283	NOUN
dpc-2446	81	4	.	.	PUNCT
dpc-2446	82	1	2	2	X
dpc-2446	82	2	.	.	X
dpc-2446	82	3	farinazzo	farinazzo	PROPN
dpc-2446	82	4	e	e	PROPN
dpc-2446	82	5	,	,	PUNCT
dpc-2446	82	6	zelin	zelin	PROPN
dpc-2446	82	7	e	e	PROPN
dpc-2446	82	8	,	,	PUNCT
dpc-2446	82	9	agozzino	agozzino	PROPN
dpc-2446	82	10	m	m	PROPN
dpc-2446	82	11	,	,	PUNCT
dpc-2446	82	12	et	et	PROPN
dpc-2446	82	13	al	al	PROPN
dpc-2446	82	14	.	.	PUNCT
dpc-2446	82	15	regression	regression	NOUN
dpc-2446	82	16	of	of	ADP
dpc-2446	82	17	nevi	nevi	ADJ
dpc-2446	82	18	,	,	PUNCT
dpc-2446	82	19	vitiligo	vitiligo	NOUN
dpc-2446	82	20	-	-	PUNCT
dpc-2446	82	21	like	like	ADJ
dpc-2446	82	22	depigmentation	depigmentation	NOUN
dpc-2446	82	23	and	and	CCONJ
dpc-2446	82	24	halo	halo	NOUN
dpc-2446	82	25	phenomenon	phenomenon	NOUN
dpc-2446	82	26	may	may	AUX
dpc-2446	82	27	indicate	indicate	VERB
dpc-2446	82	28	response	response	NOUN
dpc-2446	82	29	to	to	ADP
dpc-2446	82	30	immunotherapy	immunotherapy	NOUN
dpc-2446	82	31	and	and	CCONJ
dpc-2446	82	32	targeted	target	VERB
dpc-2446	82	33	therapy	therapy	NOUN
dpc-2446	82	34	in	in	ADP
dpc-2446	82	35	melanoma	melanoma	NOUN
dpc-2446	82	36	.	.	PUNCT
dpc-2446	83	1	melanoma	melanoma	NOUN
dpc-2446	83	2	res	re	NOUN
dpc-2446	83	3	.	.	PUNCT
dpc-2446	84	1	2021;31(6):582	2021;31(6):582	NUM
dpc-2446	84	2	-	-	SYM
dpc-2446	84	3	585	585	NUM
dpc-2446	84	4	.	.	PUNCT
dpc-2446	84	5	doi:10.1097	doi:10.1097	NOUN
dpc-2446	84	6	/cmr.0000000000000776	/cmr.0000000000000776	X
dpc-2446	84	7	.	.	PUNCT
dpc-2446	85	1	pmid	pmid	NOUN
dpc-2446	85	2	:	:	PUNCT
dpc-2446	85	3	34433200	34433200	NUM
dpc-2446	85	4	.	.	PUNCT
dpc-2446	86	1	3	3	X
dpc-2446	86	2	.	.	X
dpc-2446	86	3	zhao	zhao	PROPN
dpc-2446	86	4	cy	cy	PROPN
dpc-2446	86	5	,	,	PUNCT
dpc-2446	86	6	hwang	hwang	PROPN
dpc-2446	86	7	sje	sje	PROPN
dpc-2446	86	8	,	,	PUNCT
dpc-2446	86	9	wakade	wakade	NOUN
dpc-2446	86	10	d	d	NOUN
dpc-2446	86	11	,	,	PUNCT
dpc-2446	86	12	carlos	carlos	PROPN
dpc-2446	86	13	g	g	PROPN
dpc-2446	86	14	,	,	PUNCT
dpc-2446	86	15	anforth	anforth	PROPN
dpc-2446	86	16	r	r	NOUN
dpc-2446	86	17	,	,	PUNCT
dpc-2446	86	18	fernández	fernández	PROPN
dpc-2446	86	19	-	-	PUNCT
dpc-2446	86	20	peñas	peñas	PROPN
dpc-2446	86	21	p.	p.	NOUN
dpc-2446	86	22	melanocytic	melanocytic	ADJ
dpc-2446	86	23	lesion	lesion	NOUN
dpc-2446	86	24	evolution	evolution	NOUN
dpc-2446	86	25	patterns	pattern	NOUN
dpc-2446	86	26	with	with	ADP
dpc-2446	86	27	targeted	target	VERB
dpc-2446	86	28	therapies	therapy	NOUN
dpc-2446	86	29	and	and	CCONJ
dpc-2446	86	30	immunotherapies	immunotherapy	NOUN
dpc-2446	86	31	for	for	ADP
dpc-2446	86	32	advanced	advanced	ADJ
dpc-2446	86	33	metastatic	metastatic	ADJ
dpc-2446	86	34	melanoma	melanoma	NOUN
dpc-2446	86	35	:	:	PUNCT
dpc-2446	86	36	an	an	DET
dpc-2446	86	37	observational	observational	ADJ
dpc-2446	86	38	study	study	NOUN
dpc-2446	86	39	.	.	PUNCT
dpc-2446	87	1	australas	australas	PROPN
dpc-2446	87	2	j	j	PROPN
dpc-2446	87	3	dermatol	dermatol	NOUN
dpc-2446	87	4	.	.	PUNCT
dpc-2446	88	1	2017;58(4):292	2017;58(4):292	NUM
dpc-2446	88	2	-	-	SYM
dpc-2446	88	3	298	298	NUM
dpc-2446	88	4	.	.	PUNCT
dpc-2446	89	1	doi:10.1111	doi:10.1111	ADJ
dpc-2446	89	2	/	/	SYM
dpc-2446	89	3	ajd.12645	ajd.12645	PROPN
dpc-2446	89	4	.	.	PUNCT
dpc-2446	90	1	pmid	pmid	NOUN
dpc-2446	90	2	:	:	PUNCT
dpc-2446	90	3	28707403	28707403	NUM
dpc-2446	90	4	.	.	PUNCT
dpc-2446	91	1	figure	figure	NOUN
dpc-2446	91	2	2	2	NUM
dpc-2446	91	3	.	.	PUNCT
dpc-2446	91	4	clinical	clinical	ADJ
dpc-2446	91	5	images	image	NOUN
dpc-2446	91	6	of	of	ADP
dpc-2446	91	7	patient	patient	NOUN
dpc-2446	91	8	2	2	NUM
dpc-2446	91	9	:	:	SYM
dpc-2446	91	10	2021	2021	NUM
dpc-2446	91	11	(	(	PUNCT
dpc-2446	91	12	left	leave	VERB
dpc-2446	91	13	)	)	PUNCT
dpc-2446	91	14	and	and	CCONJ
dpc-2446	91	15	2022	2022	NUM
dpc-2446	91	16	(	(	PUNCT
dpc-2446	91	17	right	right	NOUN
dpc-2446	91	18	)	)	PUNCT
dpc-2446	91	19	.	.	PUNCT
dpc-2446	92	1	three	three	NUM
dpc-2446	92	2	lesions	lesion	NOUN
dpc-2446	92	3	registered	register	VERB
dpc-2446	92	4	in	in	ADP
dpc-2446	92	5	digital	digital	ADJ
dpc-2446	92	6	monitoring	monitoring	NOUN
dpc-2446	92	7	of	of	ADP
dpc-2446	92	8	patient	patient	NOUN
dpc-2446	92	9	2	2	NUM
dpc-2446	92	10	.	.	PUNCT
dpc-2446	92	11	(	(	PUNCT
dpc-2446	92	12	d1	d1	NOUN
dpc-2446	92	13	-	-	PUNCT
dpc-2446	92	14	f1	f1	NOUN
dpc-2446	92	15	)	)	PUNCT
dpc-2446	92	16	first	first	ADJ
dpc-2446	92	17	row	row	NOUN
dpc-2446	92	18	shows	show	VERB
dpc-2446	92	19	these	these	DET
dpc-2446	92	20	benign	benign	ADJ
dpc-2446	92	21	melanocytic	melanocytic	ADJ
dpc-2446	92	22	nevi	nevi	NOUN
dpc-2446	92	23	in	in	ADP
dpc-2446	92	24	2021	2021	NUM
dpc-2446	92	25	,	,	PUNCT
dpc-2446	92	26	while	while	SCONJ
dpc-2446	92	27	on	on	ADP
dpc-2446	92	28	nivolumab	nivolumab	NOUN
dpc-2446	92	29	treatment	treatment	NOUN
dpc-2446	92	30	.	.	PUNCT
dpc-2446	93	1	(	(	PUNCT
dpc-2446	93	2	d2	d2	NOUN
dpc-2446	93	3	-	-	PUNCT
dpc-2446	93	4	f2	f2	PROPN
dpc-2446	93	5	)	)	PUNCT
dpc-2446	93	6	second	second	ADJ
dpc-2446	93	7	row	row	NOUN
dpc-2446	93	8	displays	display	VERB
dpc-2446	93	9	the	the	DET
dpc-2446	93	10	same	same	ADJ
dpc-2446	93	11	lesions	lesion	NOUN
dpc-2446	93	12	one	one	NUM
dpc-2446	93	13	year	year	NOUN
dpc-2446	93	14	later	later	ADV
dpc-2446	93	15	in	in	ADP
dpc-2446	93	16	2022	2022	NUM
dpc-2446	93	17	,	,	PUNCT
dpc-2446	93	18	6	6	NUM
dpc-2446	93	19	months	month	NOUN
dpc-2446	93	20	after	after	ADP
dpc-2446	93	21	finishing	finish	VERB
dpc-2446	93	22	treatment	treatment	NOUN
dpc-2446	93	23	with	with	ADP
dpc-2446	93	24	nivolumab	nivolumab	NOUN
dpc-2446	93	25	.	.	PUNCT
dpc-2446	94	1	research	research	NOUN
dpc-2446	94	2	letter	letter	NOUN
dpc-2446	94	3	|	|	ADV
dpc-2446	94	4	dermatol	dermatol	ADJ
dpc-2446	94	5	pract	pract	NOUN
dpc-2446	94	6	concept	concept	NOUN
dpc-2446	94	7	.	.	PUNCT
dpc-2446	95	1	2023;13(1):e2023022	2023;13(1):e2023022	NUM
dpc-2446	95	2	5	5	NUM
dpc-2446	95	3	9	9	NUM
dpc-2446	95	4	.	.	PUNCT
dpc-2446	96	1	lallas	lallas	PROPN
dpc-2446	96	2	a	a	PROPN
dpc-2446	96	3	,	,	PUNCT
dpc-2446	96	4	apalla	apalla	PROPN
dpc-2446	96	5	z	z	PROPN
dpc-2446	96	6	,	,	PUNCT
dpc-2446	96	7	kyrgidis	kyrgidi	VERB
dpc-2446	96	8	a	a	PRON
dpc-2446	96	9	,	,	PUNCT
dpc-2446	96	10	et	et	PROPN
dpc-2446	96	11	al	al	PROPN
dpc-2446	96	12	.	.	PROPN
dpc-2446	96	13	second	second	ADJ
dpc-2446	96	14	primary	primary	ADJ
dpc-2446	96	15	melanomas	melanomas	NOUN
dpc-2446	96	16	in	in	ADP
dpc-2446	96	17	a	a	DET
dpc-2446	96	18	cohort	cohort	NOUN
dpc-2446	96	19	of	of	ADP
dpc-2446	96	20	977	977	NUM
dpc-2446	96	21	melanoma	melanoma	NOUN
dpc-2446	96	22	patients	patient	NOUN
dpc-2446	96	23	within	within	ADP
dpc-2446	96	24	the	the	DET
dpc-2446	96	25	first	first	ADJ
dpc-2446	96	26	5	5	NUM
dpc-2446	96	27	  	  	SPACE
dpc-2446	96	28	years	year	NOUN
dpc-2446	96	29	of	of	ADP
dpc-2446	96	30	monitoring	monitoring	NOUN
dpc-2446	96	31	.	.	PUNCT
dpc-2446	97	1	j	j	PROPN
dpc-2446	97	2	am	be	AUX
dpc-2446	97	3	acad	acad	ADJ
dpc-2446	97	4	dermatol	dermatol	NOUN
dpc-2446	97	5	.	.	PUNCT
dpc-2446	98	1	2020;82(2):398	2020;82(2):398	NUM
dpc-2446	98	2	-	-	PUNCT
dpc-2446	98	3	406	406	NUM
dpc-2446	98	4	.	.	PUNCT
dpc-2446	98	5	doi:10.1016	doi:10.1016	PROPN
dpc-2446	98	6	/	/	SYM
dpc-2446	98	7	j.jaad.2019.08.074	j.jaad.2019.08.074	PROPN
dpc-2446	98	8	.	.	PUNCT
dpc-2446	99	1	pmid	pmid	NOUN
dpc-2446	99	2	:	:	PUNCT
dpc-2446	99	3	31499156	31499156	NUM
dpc-2446	99	4	.	.	PUNCT
dpc-2446	100	1	8	8	NUM
dpc-2446	100	2	.	.	X
dpc-2446	100	3	nanda	nanda	PROPN
dpc-2446	100	4	jk	jk	PROPN
dpc-2446	100	5	,	,	PUNCT
dpc-2446	100	6	dusza	dusza	PROPN
dpc-2446	100	7	sw	sw	PROPN
dpc-2446	100	8	,	,	PUNCT
dpc-2446	100	9	navarrete	navarrete	NOUN
dpc-2446	100	10	-	-	PUNCT
dpc-2446	100	11	dechent	dechent	NOUN
dpc-2446	100	12	c	c	NOUN
dpc-2446	100	13	,	,	PUNCT
dpc-2446	100	14	liopyris	liopyris	PROPN
dpc-2446	100	15	k	k	PROPN
dpc-2446	100	16	,	,	PUNCT
dpc-2446	100	17	marghoob	marghoob	NOUN
dpc-2446	100	18	aa	aa	NOUN
dpc-2446	100	19	,	,	PUNCT
dpc-2446	100	20	marchetti	marchetti	PROPN
dpc-2446	100	21	ma	ma	PROPN
dpc-2446	100	22	.	.	PROPN
dpc-2446	100	23	incidence	incidence	NOUN
dpc-2446	100	24	of	of	ADP
dpc-2446	100	25	new	new	ADJ
dpc-2446	100	26	primary	primary	ADJ
dpc-2446	100	27	cutaneous	cutaneous	ADJ
dpc-2446	100	28	melanoma	melanoma	NOUN
dpc-2446	100	29	in	in	ADP
dpc-2446	100	30	patients	patient	NOUN
dpc-2446	100	31	with	with	ADP
dpc-2446	100	32	metastatic	metastatic	ADJ
dpc-2446	100	33	melanoma	melanoma	NOUN
dpc-2446	100	34	treated	treat	VERB
dpc-2446	100	35	with	with	ADP
dpc-2446	100	36	immune	immune	ADJ
dpc-2446	100	37	checkpoint	checkpoint	NOUN
dpc-2446	100	38	inhibitors	inhibitor	NOUN
dpc-2446	100	39	.	.	PUNCT
dpc-2446	101	1	jama	jama	PROPN
dpc-2446	101	2	dermatology	dermatology	PROPN
dpc-2446	101	3	.	.	PUNCT
dpc-2446	102	1	2021;157(1):79	2021;157(1):79	PROPN
dpc-2446	102	2	.	.	PUNCT
dpc-2446	103	1	doi:10.1001	doi:10.1001	PROPN
dpc-2446	103	2	/	/	SYM
dpc-2446	103	3	jamadermatol.2020.3671	jamadermatol.2020.3671	PROPN
dpc-2446	103	4	.	.	PUNCT
dpc-2446	104	1	pmid	pmid	NOUN
dpc-2446	104	2	:	:	PUNCT
dpc-2446	104	3	32936222	32936222	NUM
dpc-2446	104	4	.	.	PUNCT
dpc-2446	105	1	pmcid	pmcid	NOUN
dpc-2446	105	2	:	:	PUNCT
dpc-2446	105	3	pmc7495326	pmc7495326	NOUN
dpc-2446	105	4	.	.	PUNCT